Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed with the gene therapy. The FDA on Friday adjusted the label for Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback